A study in Israel, comparing use of ustekinumab (Stelara) and 3 other biologics used to treat inflammatory conditions has found that patients stayed on the drug longer compared with its comparators.
The authors of the study conducted a “drug survival” analysis among 907 patients with severe psoriasis who received adalimumab (Humira), infliximab (Remicade), etanercept (Enbrel), and ustekinumab for the treatment of psoriasis, using data drawn from a large health maintenance organization in Israel.
In their patient cohort, the authors documented 1575 biologic treatments and 865 discontinuation of treatments. Ustekinumab, which inhibits interleukin 12 and 23, had a significantly higher survival rate (40.8 months) than either one of the other 3 drugs, all tumor necrosis factor inhibitors. Adalimumab averaged at 26.4 months, etanercept at 26.35 months, and infliximab at 23.9 months.
Important positive predictors of drug survival, the authors report, included treatment naivety and concomitant methotrexate intake. On the other hand, duration of the previous treatment as well as female gender were negative predictors of survival.
The authors concluded that biologics efficacy in real-life clinical practice decreases over time. They also noted that while ustekinumab survived longer among patients, most of its use was as a third-line in patients with severe psoriasis.
Reference
Shalom G, Cohen AD, Ziv M, et al. Biologic drug survival in Israeli psoriasis patients [published online December 28, 2016]. J Am Acad Dermatol. pii: S0190-9622(16)31008-8. doi: 10.1016/j.jaad.2016.10.033.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Sustainable Biosimilar Markets Achieve Widespread Market Uptake Through Collective Action
April 22nd 2024Despite current challenges in biosimilar market growth due to stakeholder disagreements, a recent commentary proposes that applying collective action theory can achieve widespread biosimilar market uptake by fostering collaboration for long-term benefits.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.